Preservation strategies to reduce ischemic injury in kidney transplantation: Pharmacological and genetic approaches

Current Opinion in Organ Transplantation

Volumn 16, Issue 2, 2011, Pages 180-187

  Chatauret, Nicolas ^a,b,e   Thuillier, Raphael ^a,b,c,e   Hauet, Thierry ^a,b,c,d,e  

^a INSERM   (France)

^b UNIVERSITÉ DE POITIERS   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d CEMAGREF   (France)

^e FLIRT: Federation Pour l'Etude de l'Ischemie Reperfusion en Transplantation   (France)

Author keywords

cold storage; ex vivo treatment; gene therapy; pharmacological supplementation; RNAi

Indexed keywords

1 [7 (4 FLUOROPHENYL) 1,2,3,4 TETRAHYDRO 8 (4 PYRIDYL)PYRAZOLO[5,1 C][1,2,4]TRIAZIN 2 YL] 2 PHENYLETHANEDIONE; ALPHA TOCOPHEROL; ALPRAZOLAM; AMIFOSTINE; ANTISENSE OLIGONUCLEOTIDE; ARGININE; BETA CAROTENE; CARNITINE; DEXAMETHASONE; DOXYCYCLINE; ERDOSTEINE; ERITORAN; ERYTHROPOIETIN; ETANERCEPT; INDOMETACIN; ISOFLURANE; LIOTHYRONINE; MANNITOL; MATRIX METALLOPROTEINASE INHIBITOR; MELAGATRAN; MELATONIN; MICRORNA; PROMETHAZINE; PROPOFOL; PYCNOGENOL; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; THIOPENTAL; TRIMETAZIDINE; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; COMPLEMENT SYSTEM; DRUG MECHANISM; GENE EXPRESSION; GENE SILENCING; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNE RESPONSE; INFLAMMATION; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MITOCHONDRION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ORGAN PRESERVATION; OUTCOME ASSESSMENT; OXIDATIVE STRESS; QUALITY OF LIFE; REPERFUSION INJURY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM;

COLD TEMPERATURE; GENE THERAPY; HUMANS; KIDNEY TRANSPLANTATION; NEPHRECTOMY; ORGAN PRESERVATION; ORGAN PRESERVATION SOLUTIONS; REPERFUSION INJURY; TISSUE DONORS; TREATMENT OUTCOME;

EID: 79954616402     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283446b1d     Document Type: Article

References (139)

1. Simmons MN, Schreiber MJ, Gill IS. Surgical renal ischemia: a contemporary overview. J Urol 2008; 180:19-30.
2. Kosieradzki M, Rowinski W. Ischemia/reperfusion injury in kidney transplantation: mechanisms and prevention. Transplant Proc 2008; 40:3279-3288.
3. Favreau F, Thuillier R, Cau J, et al. Antithrombin therapy during warm ischemia and cold preservation prevents chronic kidney graft fibrosis in a DCD model. Am J Transplant 2010; 10:30-39.
4. Giraud S, Thuillier R, Belliard A, et al. Direct thrombin inhibitor prevents delayed graft function in a porcine model of renal transplantation. Transplantation 2009; 87:1636-1644.
5. Thuillier R, Favreau F, Celhay O, et al. Thrombin inhibition during kidney ischemia-reperfusion reduces chronic graft inflammation and tubular atrophy. Transplantation 2010; 90:612-621.
6. Dragun D, Hoff U, Park JK, et al. Ischemia-reperfusion injury in renal transplantation is independent of the immunologic background. Kidney Int 2000; 58:2166-2177.
7. Cassie S, Masterson MF, Polukoshko A, et al. Ischemia/reperfusion induces the recruitment of leukocytes from whole blood under flow conditions. Free Radic Biol Med 2004; 36:1102-1111. (Pubitemid 38479864)
8. Salahudeen AK. Cold ischemic injury of transplanted organs: some new strategies against an old problem. Am J Transplant 2004; 4:1. (Pubitemid 38155482)
9. Jayle C, Favreau F, Zhang K, et al. Comparison of protective effects of trimetazidine against experimental warm ischemia of different durations: early and long-termeffects in a pig kidney model. Am J Physiol 2007; 292:F1082-F1093. (Pubitemid 46393435)
10. Jang HR, Ko GJ, Wasowska BA, Rabb H. The interaction between ischemia- reperfusion and immune responses in the kidney. J Mol Med (Berlin, Germany) 2009; 9:859-864.
11. Jang HR, Rabb H. The innate immune response in ischemic acute kidney injury. Clin Immunol (Orlando, FL) 2009; 130:41-50.
12. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev 2002; 2:725-734.
13. Cummins EP, Berra E, Comerford KM, et al. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci U S A 2006; 103:18154-18159. (Pubitemid 44871628)
14. O'Valle F, Del Moral RG, Benitez Mdel C, et al. Poly[ADP-ribose] polymerase-1 expression is related to cold ischemia, acute tubular necrosis, and delayed renal function in kidney transplantation. PLoS One 2009; 4:e7138.
15. Oztas E, Guven A, Turk E, et al. 3-Aminobenzamide, a poly ADP ribose polymerase inhibitor, attenuates renal ischemia/reperfusion injury. Renal Failure 2009; 31:393-399.
16. Choi DE, Jeong JY, Lim BJ, et al. Pretreatment with the tumor necrosis factoralpha blocker etanercept attenuated ischemia-reperfusion renal injury. Transplant Proc 2009; 41:3590-3596.
17. Li J, Gong Q, Zhong S, et al. Neutralization of the extracellular HMGB1 released by ischaemic damaged renal cells protects against renal ischaemia- reperfusion injury. Nephrol Dial Transplant 2011; 26:469-478.
18. Liu M, Gu M, Xu D, et al. Protective effects of Toll-like receptor 4 inhibitor eritoran on renal ischemia-reperfusion injury. Transplant Proc 2010; 42:1539-1544.
19. Asgari E, Zhou W, Sacks S. Complement in organ transplantation. Curr Opin Organ Transplant 2010; 15:486-491.
20. Vieyra MB, Heeger PS. Novel aspects of complement in kidney injury. Kidney Int 2010; 77:495-499.
21. Zheng X, Feng B, Chen G, et al. Preventing renal ischemia-reperfusion injury using small interfering RNA by targeting complement 3 gene. AmJ Transplant 2006; 6:2099-2108. (Pubitemid 44199544)
22. Zheng X, Zhang X, Sun H, et al. Protection of renal ischemia injury using combination gene silencing of complement 3 and caspase 3 genes. Transplantation 2006; 82:1781-1786. (Pubitemid 46035667)
23. Zheng X, Zhang X, Feng B, et al. Gene silencing of complement C5a receptor using siRNA for preventing ischemia/reperfusion injury. Am J Pathol 2008; 173:973-980.
24. Lewis AG, Kohl G, Ma Q, et al. Pharmacological targeting of C5a receptors during organ preservation improves kidney graft survival. Clin Exp Immunol 2008; 153:117-126. (Pubitemid 351809344)
25. Castellano G, Melchiorre R, Loverre A, et al. Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion- induced renal damage. Am J Pathol 2010; 176:1648-1659.
26. Chen J, Crispin JC, Dalle Lucca J, Tsokos GC. A novel inhibitor of the alternative pathway of complement attenuates intestinal ischemia/reperfusion- induced injury. J Surg Res 2009. [Epub ahead of print]
27. Guo X, Gerl RE, Schrader JW. Defining the involvement of p38alpha MAPK in the production of anti and proinflammatory cytokines using an SB 203580- resistant form of the kinase. J Biol Chem 2003; 278:22237-22242. (Pubitemid 36830270)
28. Maulik N, Yoshida T, Zu YL, et al. Ischemic preconditioning triggers tyrosine kinase signaling: a potential role for MAPKAP kinase 2. Am J Physiol 1998; 275:H1857-H1864.
29. Ollinger R, Thomas M, Kogler P, et al. Blockade of p38 MAPK inhibits chronic allograft vasculopathy. Transplantation 2008; 85:293-297. (Pubitemid 351156861)
30. Doucet C, Milin S, Favreau F, et al. A p38 mitogen-activated protein kinase inhibitor protects against renal damage in a nonheart-beating donor model. Am J Physiol 2008; 295:F179-F191.
31. Desurmont T, Giraud S, Cau J, et al. Trophic factor and FR167653 supplementation during cold storage rescue chronic renal injury. J Urol (in press).
32. Khan NA, Susa D, van den Berg JW, et al. Amelioration of renal ischaemia- reperfusion injury by synthetic oligopeptides related to human chorionic gonadotropin. Nephrol Dial Transplant 2009; 24:2701-2708.
33. Novak KB, Le HD, Christison-Lagay ER, et al. Effects of metalloproteinase inhibition in a murine model of renal ischemia reperfusion injury. Pediatric Res 2009; 67:257-262.
34. Schneider R, Meusel M, Renker S, et al. Low-dose indomethacin after ischemic acute kidney injury prevents down regulation of Oat1/3 and improves renal outcome. Am J Physiol 2009; 297:F1614-F1621.
35. Hertig A, Rondeau E. Role of the coagulation/fibrinolysis system in fibrinassociated glomerular injury. J Am Soc Nephrol 2004; 15:844-853. (Pubitemid 38375303)
36. Celi A, Pellegrini G, Lorenzet R, et al. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci U S A 1994; 91:8767-8771.
37. Cicco G, Panzera PC, Catalano G, Memeo V. Microcirculation and reperfusion injury in organ transplantation. Adv Exp Med Biol 2005; 566:363-373. (Pubitemid 43779524)
38. De Vries DK, Lindeman JH, Tsikas D, et al. Early renal ischemia-reperfusion injury in humans is dominated by IL-6 release from the allograft. Am J Transplant 2009; 9:1574-1584.
39. Lisman T. Activation of coagulation by living donor kidney transplants early after reperfusion. Am J Transplant 2010; 10:434.
40. Li C, Jackson RM. Reactive species mechanisms of cellular hypoxia-reoxygenation injury. Am J Physiol Cell Physiol 2002; 282:C227-C241. (Pubitemid 34663181)
41. Thuillier R, Tillement JP, Hauet T. Renal protective effect of metabolic therapy in patients with coronary artery disease and diabetes: from bench to bed side. Curr Pharm Des 2009; 15:863-882.
42. Nakagawa T, Kang DH, Ohashi R, et al. Tubulointerstitial disease: role of ischemia and microvascular disease. Curr Opin Nephrol Hypertens 2003; 12:233-241. (Pubitemid 36578057)
43. Djamali A, Vidyasagar A, Adulla M, et al. Nox-2 is a modulator of fibrogenesis in kidney allografts. Am J Transplant 2009; 9:74-82.
44. Kim J, Seok YM, Jung KJ, Park KM. Reactive oxygen species/oxidative stress contributes to progression of kidney fibrosis following transient ischemic injury in mice. Am J Physiol 2009; 297:F461-F470.
45. Calvert JW, Coetzee WA, Lefer D. Novel insights into hydrogen sulfide mediated cytoprotection. Antioxid Redox Signal 2009; 12:1203-1217.
46. Szabo C. Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 2007; 6:917-935. (Pubitemid 350042399)
47. Bos EM, Leuvenink HG, Snijder PM, et al. Hydrogen sulfide-induced hypometabolism prevents renal ischemia/reperfusion injury. J Am Soc Nephrol 2009; 20:1901-1905.
48. Hosgood SA, Nicholson ML. Hydrogen sulphide ameliorates ischaemia- reperfusion injury in an experimental model of nonheart-beating donor kidney transplantation. Br J Surgery 2009; 89:1169-1175.
49. Simon F, Scheuerle A, Groger M, et al. Effects of intravenous sulfide during porcine aortic occlusion-induced kidney ischemia/reperfusion injury. Shock 2011; 35:156-163.
50. Ryter SW, Otterbein LE, Morse D, Choi AM. Heme oxygenase/carbon monoxide signaling pathways: regulation and functional significance. Mol Cell Biochem 2002; 234-235:249-263. (Pubitemid 34777864)
51. Nath KA, Haggard JJ, Croatt AJ, et al. The indispensability of heme oxygenase-1 in protecting against acute heme protein-induced toxicity in vivo. Am J Pathol 2000; 156:1527-1535. (Pubitemid 30646692)
52. Salom MG, Ceron SN, Rodriguez F, et al. Heme oxygenase-1 induction improves ischemic renal failure: role of nitric oxide and peroxynitrite. Am J Physiol Heart Circ Physiol 2007; 293:H3542-H3549. (Pubitemid 350230898)
53. Toda N, Takahashi T, Mizobuchi S, et al. Tin chloride pretreatment prevents renal injury in rats with ischemic acute renal failure. Crit Care Med 2002; 30:1512-1522. (Pubitemid 34756234)
54. Chok MK, Ferlicot S, Conti M, et al. Renoprotective potency of heme oxygenase-1 induction in rat renal ischemia-reperfusion. Inflamm Allergy Drug Targets 2009; 8:252-259.
55. Shi Q, Feng YN, Fang J, Xu K. Pretreatment with glutamine attenuates anoxia/ reoxygenation injury of human proximal renal tubular epithelial cells via induction of heme oxygenase-1. Pharmacology 2009; 84:1-8.
56. Kotsch K, Martins PN, Klemz R, et al. Heme oxygenase-1 ameliorates ischemia/reperfusion injury by targeting dendritic cell maturation and migration. Antioxid Redox Signal 2007; 9:2049-2063. (Pubitemid 350059022)
57. Kirkby K, Baylis C, Agarwal A, et al. Intravenous bilirubin provides incomplete protection against renal ischemia-reperfusion injury in vivo. Am J Physiol 2007; 292:F888-F894. (Pubitemid 46220558)
58. Wiesel P, Patel AP, DiFonzo N, et al. Endotoxin-induced mortality is related to increased oxidative stress and end-organ dysfunction, not refractory hypotension, in heme oxygenase-1-deficient mice. Circulation 2000; 102:3015-3022.
59. Abraham NG, Kushida T, McClung J, et al. Heme oxygenase-1 attenuates glucose-mediated cell growth arrest and apoptosis in human microvessel endothelial cells. Circulation Res 2003; 93:507-514. (Pubitemid 37163230)
60. Quan S, Yang L, Shenouda S, et al. Functional expression of human heme oxygenase-1 (HO-1) driven by HO-1 promoter in vitro and in vivo. J Cell Biochem 2002; 85:410-421. (Pubitemid 34274908)
61. Otterbein LE, Kolls JK, Mantell LL, et al. Exogenous administration of heme oxygenase-1 by gene transfer provides protection against hyperoxia-induced lung injury. J Clin Invest 1999; 103:1047-1054. (Pubitemid 29169613)
62. Ghosh S, Gal J, Marczin N. Carbon monoxide: endogenous mediator, potential diagnostic and therapeutic target. Ann Med 2010; 42:1-12.
63. Neto JS, Nakao A, Toyokawa H, et al. Low-dose carbon monoxide inhalation prevents development of chronic allograft nephropathy. Am J Physiol 2006; 290:F324-F334. (Pubitemid 43738984)
64. Yoshida J, Ozaki KS, Nalesnik MA, et al. Ex vivo application of carbon monoxide in UW solution prevents transplant-induced renal ischemia/reperfusion injury in pigs. Am J Transplant 2010; 10:763-772.
65. Chatterjee PK. Water-soluble carbon monoxide-releasing molecules: helping to elucidate the vascular activity of the 'silent killer'. Br J Pharmacol 2004; 142:391-393. (Pubitemid 38869851)
66. Vera T, Henegar JR, Drummond HA, et al. Protective effect of carbon monoxide-releasing compounds in ischemia-induced acute renal failure. J Am Soc Nephrol 2005; 16:950-958. (Pubitemid 41710305)
67. Sandouka A, Fuller BJ, Mann BE, et al. Treatment with CO-RMs during cold storage improves renal function at reperfusion. Kidney Int 2006; 69:239-247. (Pubitemid 43323073)
68. Mason RP, Kubant R, Jacob RF, et al. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity. J Cardiovasc Pharmacol 2006; 48:862-869. (Pubitemid 44276465)
69. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000; 408:239-247.
70. Basireddy M, Isbell TS, Teng X, et al. Effects of sodium nitrite on ischemia- reperfusion injury in the rat kidney. Am J Physiol 2006; 290:F779-F786. (Pubitemid 43724935)
71. Tripatara P, Patel NS, Webb A, et al. Nitrite-derived nitric oxide protects the rat kidney against ischemia/reperfusion injury in vivo: role for xanthine oxidoreductase. J Am Soc Nephrol 2007; 18:570-580. (Pubitemid 46193322)
72. Barakat N, Hussein AA, Abdel-Maboud M, El-Shair MA, Mostafa A, Abol- Enein H. Ischaemia-reperfusion injury in renal transplantation: the role of nitric oxide in an experimental rat model. BJU Int 2010; 106:1230-1236.
73. Talab SS, Emami H, Elmi A, et al. Chronic lithium treatment protects the rat kidney against ischemia/reperfusion injury: the role of nitric oxide and cyclooxygenase pathways. Eur J Pharmacol 2010; 647:171-177.
74. Fantini E, Demaison L, Sentex E, et al. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol 1994; 26:949-958. (Pubitemid 24279511)
75. Ancerewicz J, Migliavacca E, Carrupt PA, et al. Structure-property relationships of trimetazidine derivatives and model compounds as potential antioxidants. Free Radical Biol Med 1998; 25:113-120. (Pubitemid 28285278)
76. Reymond F, Steyaert G, Carrupt PA, et al. The pH-partition profile of the antiischemic drug trimetazidine may explain its reduction of intracellular acidosis. Pharm Res 1999; 16:616-624. (Pubitemid 29227088)
77. Goujon JM, Vandewalle A, Baumert H, et al. Influence of cold-storage conditions on renal function of autotransplanted large pig kidneys. Kidney Int 2000; 58:838-850. (Pubitemid 30620034)
78. Hauet T, Goujon JM, Vandewalle A, et al. Trimetazidine reduces renal dysfunction by limiting the cold ischemia/reperfusion injury in autotransplanted pig kidneys. J Am Soc Nephrol 2000; 11:138-148. (Pubitemid 30020436)
79. Ferreyra C, O'Valle F, Osorio JM, et al. Effect of preconditioning with triiodothyronine on renal ischemia/reperfusion injury and poly(ADP-ribose) polymerase expression in rats. Transplant Proc 2009; 41:2073-2075.
80. Kucuk A, Kabadere S, Tosun M, et al. Protective effects of doxycycline in ischemia/reperfusion injury on kidney. J Physiol Biochem 2009; 65:183-191.
81. Chok MK, Conti M, Almolki A, et al. Renoprotective potency of amifostine in rat renal ischaemia-reperfusion. Nephrol Dial Transplant 2010; 25:3845-51.
82. Yurdakul T, Kulaksizoglu H, Piskin MM, et al. Combination antioxidant effect of alpha-tocoferol and erdosteine in ischemia-reperfusion injury in rat model. Int Urol Nephrol 2009; 42:647-655.
83. Ersoz N, Guven A, Cayci T, et al. Comparison of the efficacy of melatonin and 1400W on renal ischemia/reperfusion injury: a role for inhibiting iNOS. Renal Failure 2009; 31:704-710.
84. Ozer Sehirli A, Sener G, Ercan F. Protective effects of pycnogenol against ischemia reperfusion-induced oxidative renal injury in rats. Renal Failure 2009; 31:690-697.
85. Hosseini F, Naseri MK, Badavi M, et al. Protective effect of beta carotene pretreatment on renal ischemia/reperfusion injury in rat. Pakistan J Biol Sci 2009; 12:1140-1145.
86. Lee JY, Kim HS, Park CS, Kim MC. Erdosteine in renal ischemia-reperfusion injury: an experimental study in pigs. J Vet Med Sci/ Jpn Soc Vet Sci 2009; 72:127-130.
87. Hagiwara S, Koga H, Iwasaka H, et al. ETS-GS, a new antioxidant, ameliorates renal ischemia-reperfusion injury in a rodent model. J Surg Res 2010. [Epub ahead of print]
88. Ye J, Li J, Yu Y, et al. L-carnitine attenuates oxidant injury in HK-2 cells via ROS-mitochondria pathway. Regul Pept 2010; 161:58-66.
89. Tsoulfas G, Takahashi Y, Liu D, et al. Hydrodynamic plasmid DNA gene therapy model in liver transplantation. J Surg Res 2006; 135:242-249. (Pubitemid 44414892)
90. Shingu C, Koga H, Hagiwara S, et al. Hydrogen-rich saline solution attenuates renal ischemia-reperfusion injury. J Anesthesia 2010; 24:569-574.
91. Shuvaev VV, Christofidou-Solomidou M, Bhora F, et al. Targeted detoxification of selected reactive oxygen species in the vascular endothelium. J Pharm Exp Therap 2009; 331:404-411.
92. Kumar S, Allen DA, Kieswich JE, et al. Dexamethasone ameliorates renal ischemia-reperfusion injury. J Am Soc Nephrol 2009; 20:2412-2425.
93. Ishii Y, Sawada T, Murakami T, et al. Renoprotective effect of erythropoietin against ischaemia-reperfusion injury in a nonhuman primate model. Nephrol Dial Transplant 2010. [Epub ahead of print]
94. Moriyama MT, Tanaka T, Morita N, et al. Renal protective effects of erythropoietin on ischemic reperfusion injury. Cell Transplant 2010; 19:713-721.
95. Hussein AA, Shokeir AA, Sarhan ME, et al. Effects of combined erythropoietin and epidermal growth factor on renal ischaemia/reperfusion injury: a randomized experimental controlled study. BJU Int 2010; 107:323-328.
96. Zhang Y, Zou Z, Li YK, et al. Glutamine-induced heat shock protein protects against renal ischaemia-reperfusion injury in rats. Nephrology (Carlton, VIC) 2009; 14:573-580.
97. Bajwa A, Jo SK, Ye H, et al. Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury. J Am Soc Nephrol 2010; 21:955-965.
98. Kim M, Kim M, Park SW, et al. Isoflurane protects human kidney proximal tubule cells against necrosis via sphingosine kinase and sphingosine-1- phosphate generation. Am J Nephrol 2010; 31:353-362.
99. Haase VH. Hypoxia-inducible factors in the kidney. Am J Physiol 2006; 291:F271-F281. (Pubitemid 44148116)
100. Rius J, Guma M, Schachtrup C, et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 2008; 453:807-811. (Pubitemid 351793778)
101. Yang CC, Lin LC, Wu MS, et al. Repetitive hypoxic preconditioning attenuates renal ischemia/reperfusion induced oxidative injury via upregulating HIF-1 alpha-dependent bcl-2 signaling. Transplantation 2009; 88:1251-1260.
102. Yeh CH, Hsu SP, Yang CC, et al. Hypoxic preconditioning reinforces HIFalpha- dependent HSP70 signaling to reduce ischemic renal failure-induced renal tubular apoptosis and autophagy. Life Sci 2010; 86:115-123.
103. Bernhardt WM, Gottmann U, Doyon F, et al. Donor treatment with a PHDinhibitor activating HIFs prevents graft injury and prolongs survival in an allogenic kidney transplant model. Proc Natl Acad Sci U S A 2009; 106:21276-21281.
104. Pazoki-Toroudi HR, Ajami M, Habibey R. Premedication and renal preconditioning: a role for alprazolam, atropine, morphine and promethazine. Fundam Clin Pharmacol 2009; 24:189-198.
105. Dogan Z, Yuzbasioglu MF, Kurutas EB, et al. Thiopental improves renal ischemia-reperfusion injury. Renal Failure 2010; 32:391-395.
106. Yuzbasioglu MF, Aykas A, Kurutas EB, Sahinkanat T. Protective effects of propofol against ischemia/reperfusion injury in rat kidneys. Renal Failure 2010; 32:578-583.
107. Matsuyama M, Yoshimura R. Prospects of antisense oligodeoxynucleotides to alleviate renal ischaemia-reperfusion injury. Expert Opin Biol Ther 2004; 4:1931-1937. (Pubitemid 39627144)
108. Stokman G, Qin Y, Racz Z, Hamar P, Price LS. Application of siRNA in targeting protein expression in kidney disease. Adv Drug Deliv Rev 2010; 62:1378-1389.
109. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007; 59:75-86. (Pubitemid 46770900)
110. Sandovici M, Deelman LE, Benigni A, Henning RH. Towards graft-specific immune suppression: gene therapy of the transplanted kidney. Adv Drug Deliv Rev 2010; 62:1358-68.
111. Ritter T, Nosov M, Griffin MD. Gene therapy in transplantation: toward clinical trials. Curr Opin Mol Therap 2009; 11:504-512.
112. Li N, Zhou J, Weng D, et al. Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2007; 13:5847-5854. (Pubitemid 47583910)
113. Van der Wouden EA, Sandovici M, Henning RH, et al. Approaches and methods in gene therapy for kidney disease. J Pharmacol Toxicol Methods 2004; 50:13-24. (Pubitemid 38844997)
114. Isaka Y, Yamada K, Takabatake Y, et al. Electroporation-mediated HGF gene transfection protected the kidney against graft injury. Gene Ther 2005; 12:815-820. (Pubitemid 40753973)
115. Azuma H, Tomita N, Kaneda Y, et al. Transfection of NFkappaB-decoy oligodeoxynucleotides using efficient ultrasound-mediated gene transfer into donor kidneys prolonged survival of rat renal allografts. Gene Ther 2003; 10:415-425. (Pubitemid 36372449)
116. Kita J, Kobayashi E, Hishinuma A, Kaneda Y. Genetic modification of coldpreserved renal grafts using HSP70 or bcl-2 HVJ-liposome method. Transpl Immunol 2003; 11:7-14. (Pubitemid 36553278)
117. Zheng X, Lian D, Wong A, et al. Novel small interfering RNA-containing solution protecting donor organs in heart transplantation. Circulation 2009; 120:1099-1107.
118. Benigni A, Tomasoni S, Turka LA, et al. Adeno-associated virus-mediated CTLA4Ig gene transfer protects MHC-mismatched renal allografts from chronic rejection. J Am Soc Nephrol 2006; 17:1665-1672. (Pubitemid 43794669)
119. Shou Z, Xiao H, Xu Y, et al. SHARP-2 gene silencing by lentiviral-based short hairpin RNA interference prolonged rat kidney transplant recipients' survival time. J Int Med Res 2009; 37:766-778.
120. Blydt-Hansen TD, Katori M, Lassman C, et al. Gene transfer-induced local heme oxygenase-1 overexpression protects rat kidney transplants from ischemia/reperfusion injury. J Am Soc Nephrol 2003; 14:745-754. (Pubitemid 36246020)
121. Tomasoni S, Azzollini N, Casiraghi F, et al. CTLA4Ig gene transfer prolongs survival and induces donor-specific tolerance in a rat renal allograft. J Am Soc Nephrol 2000; 11:747-752. (Pubitemid 30171884)
122. Zeigler ST, Kerby JD, Curiel DT, et al. Molecular conjugate-mediated gene transfer into isolated human kidneys. Transplantation 1996; 61:812-817. (Pubitemid 26097245)
123. Kitamura M. Renal transfer of genetically engineered cells. J Am Soc Nephrol 2000; 11 (Suppl 16):S154-S158.
124. Ma J, Lau CK, Obed A, et al. A cell penetrating heme oxygenase protein protects heart graft against ischemia/reperfusion injury. Gene Ther 2009; 16:320-328.
125. Elliger SS, Elliger CA, Lang C, Watson GL. Enhanced secretion and uptake of beta-glucuronidase improves adeno-associated viral-mediatedgene therapy of mucopolysaccharidosis type VII mice. Mol Ther 2002; 5:617-626. (Pubitemid 34546092)
126. Lien YH, Lai LW, Silva AL. Pathogenesis of renal ischemia/reperfusion injury: lessons from knockout mice. Life Sci 2003; 74:543-552. (Pubitemid 37410347)
127. Sandovici M, Deelman LE, de Zeeuw D, et al. Immune modulation and graft protection by gene therapy in kidney transplantation. Eur J Pharmacol 2008; 585:261-269.
128. Phull H, Lien YH, Salkini MW, et al. Delivery of intercellular adhesion molecule-1 antisense oligonucleotides using a topical hydrogel tissue sealant in a murine partial nephrectomy/ischemia model. Urology 2008; 72:690-695.
129. Chen W, Bennett CF, Wang ME, et al. Perfusion of kidneys with unformulated 'naked' intercellular adhesion molecule-1 antisense oligodeoxynucleotides prevents ischemic/reperfusion injury. Transplantation 1999; 68:880-887. (Pubitemid 29468208)
130. Stepkowski SM, Wang ME, Condon TP, et al. Protection against allograft rejection with intercellular adhesion molecule-1 antisense oligodeoxynucleotides. Transplantation 1998; 66:699-707. (Pubitemid 28460103)
131. Kahan BD, Stepkowski S, Kilic M, et al. Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection. Transplantation 2004; 78:858-863. (Pubitemid 39298529)
132. Sato W, Takei Y, Yuzawa Y, et al. Midkine antisense oligodeoxyribonucleotide inhibits renal damage induced by ischemic reperfusion. Kidney Int 2005; 67:1330-1339. (Pubitemid 40463109)
133. Cao CC, Ding XQ, Ou ZL, et al. In vivo transfection of NF-kappaB decoy oligodeoxynucleotides attenuate renal ischemia/reperfusion injury in rats. Kidney Int 2004; 65:834-845. (Pubitemid 38251059)
134. Vos IH, Govers R, Grone HJ, et al. NFkappaB decoy oligodeoxynucleotides reduce monocyte infiltration in renal allografts. FASEB J 2000; 14:815-822. (Pubitemid 30198580)
135. Tomasoni S, Longaretti L, Azzollini N, et al. Favorable effect of cotransfection with TGF-beta and CTLA4Ig of the donor kidney on allograft survival. Am J Nephrol 2004; 24:275-283. (Pubitemid 39070109)
136. Gong N, Dong C, Chen Z, et al. Adenovirus-mediated antisense-ERK2 gene therapy attenuates chronic allograft nephropathy. Transplant Proc 2006; 38:3228-3230. (Pubitemid 44908517)
137. Yang J, Reutzel-Selke A, Steier C, et al. Targeting of macrophage activity by adenovirus-mediated intragraft overexpression of TNFRp55-Ig, IL-12p40, and vIL-10 ameliorates adenovirus-mediated chronic graft injury, whereas stimulation of macrophages by overexpression of IFN-gamma accelerates chronic graft injury in a rat renal allograft model. J Am Soc Nephrol 2003; 14:214-225. (Pubitemid 36026312)
138. Molitoris BA, Dagher PC, Sandoval RM, et al. siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol 2009; 20:1754-1764.
139. Imamura R, Isaka Y, Sandoval RM, et al. Intravital 2-photon microscopy assessment of renal protection efficacy of siRNA for p53 in experimental rat kidney transplantation models. Cell Transplant 2010. [Epub ahead of print]